#Canada #Saskatoon #ZYUS Life Sciences #UTOPIA-1 #Trichomylin®

ZYUS Life Sciences Reports Early Insights from UTOPIA-1 Trial

On January 8, 2026, ZYUS Life Sciences Corporation, a company focused on pioneering non-opioid solutions for pain management, announced promising preliminary results from its ongoing Phase 2a UTOPIA-1 (Unique Treatment of Oncology Pain in Advanced Cancer) trial. This trial specifically evaluates the safety and effectiveness of Trichomylin® softgel capsules among patients suffering from moderate to severe cancer-related pain.

Trial Highlights

The UTOPIA-1 trial adopts a single-arm, proof-of-concept format and aims to address the pressing need for effective pain management alternatives in oncology settings. Preliminary findings are based on data from the first 25% of patients enrolled in the study who have completed their treatment. Here are the essential highlights of the findings:

• - Reduction in Pain Levels: Patients experienced a notable decrease in average daily pain and pain severity.
• - Decreased Opioid Dependency: There was a significant reduction in opioid usage among patients needing additional pain relief.
• - Safety Profile: No serious adverse effects associated with Trichomylin® softgel capsules have been reported.
• - Tolerability: The capsules were generally well-received; most reported side effects were mild and occurred during dose adjustments, aligning with outcomes from the previous Phase 1 trial.

Expert Insights

Dr. Julie Stakiw, Chief Medical Officer at ZYUS, emphasized the importance of these early outcomes, which validate their trial design amid a challenging patient demographic. “This is an essential milestone in our research. The results thus far provide valuable insights into both safety and potential analgesic effectiveness as we move forward in this trial,” she stated.

Furthermore, Brent Zettl, the company's CEO, underscored that these preliminary findings stem from over seven years devoted to rigorous scientific and clinical work. While data remains early-stage, the patterns observed reinforce ZYUS's belief in Trichomylin® as a formidable option for managing cancer-related pain without resorting to opioids.

Next Steps

As the UTOPIA-1 trial advances, ZYUS aims to continue gathering critical data that could one day support the transition to later-stage trials and further cement the safety profile of their therapeutic candidate. Patients and stakeholders are encouraged to stay updated through clinicaltrials.gov under identifier NCT06533657 for more details about the ongoing study and future developments.

About ZYUS Life Sciences Corporation

ZYUS Life Sciences (TSXV: ZYUS) is at the forefront of developing innovative, cannabinoid-based pharmaceuticals aimed at transforming patient care in pain management. Committed to rigorous clinical research and intellectual property protection, ZYUS is seeking to attain regulatory approvals for its non-opioid drug solutions, focusing on significantly enhancing the quality of life for patients dealing with pain. More information can be found at www.zyus.com or by following them on social media platforms.

Conclusion

The initial results from ZYUS's Phase 2a UTOPIA-1 trial reveal a potential breakthrough in non-opioid pain management that could dramatically improve outcomes for patients facing challenging medical conditions. As the trial progresses, many will look toward ZYUS to deliver promising treatments that reduce reliance on traditional opioids while ensuring patient safety.